{"nct_id": "NCT05337137", "age": "Adults", "cancer_center_accrual_goal_upper": 0, "data_table4": "Interventional", "drug_list": {"drug": [{"drug_name": "Other: Placebo"}, {"drug_name": "Drug: Bevacizumab"}, {"drug_name": "Drug: Relatlimab"}, {"drug_name": "Drug: Nivolumab"}]}, "long_title": "A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination With Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma", "management_group_list": {"management_group": [{"is_primary": "Y", "management_group_name": "Group1"}]}, "oncology_group_list": {"oncology_group": [{"group_name": "Group1", "is_primary": "N"}]}, "phase": "PHASE1", "principal_investigator": "Bristol-Myers Squibb", "principal_investigator_institution": "Bristol-Myers Squibb", "program_area_list": {"program_area": [{"is_primary": "Y", "program_area_name": "Program1"}]}, "protocol_id": 0, "protocol_no": "", "protocol_target_accrual": 162, "protocol_type": "INTERVENTIONAL", "prior_treatment_requirements": ["Inclusion Criteria:", "* Histologically confirmed advanced/metastatic hepatocellular carcinoma (HCC)", "* Na\u00efve to systemic therapy for advanced/metastatic HCC (prior neo-adjuvant or adjuvant immunotherapy is permitted if recurrence occurs \u2265 6 months after treatment completion and the case is discussed with BMS medical team)", "* Child-Pugh score of 5 or 6 (ie, Child-Pugh A)", "* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1", "Exclude - Exclusion Criteria:", "Exclude - * Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC", "Exclude - * Prior allogenic stem cell or solid organ transplantation", "Exclude - * Untreated symptomatic central nervous system (CNS) metastases", "Exclude - * Clinically significant ascites as defined by:", "Exclude - i) Prior ascites that required treatment and requires on-going prophylaxis, or ii) Current ascites requiring treatment", "Exclude - Other protocol-defined inclusion/exclusion criteria apply"], "short_title": "A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer", "site_list": {"site": []}, "sponsor_list": {"sponsor": [{"is_principal_sponsor": "Y", "sponsor_name": "Bristol-Myers Squibb", "sponsor_protocol_no": "", "sponsor_roles": "sponsor"}]}, "staff_list": {"protocol_staff": []}, "status": "open to accrual", "summary": "The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC).", "treatment_list": {"step": [{"arm": [{"arm_code": "Arm A: Relatlimab + Nivolumab + Bevacizumab", "arm_internal_id": 0, "arm_description": {}, "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Drug: Relatlimab", "level_internal_id": 0, "level_suspended": "N"}, {"level_code": "1", "level_description": "Drug: Nivolumab", "level_internal_id": 1, "level_suspended": "N"}, {"level_code": "2", "level_description": "Drug: Bevacizumab", "level_internal_id": 2, "level_suspended": "N"}]}, {"arm_code": "Arm B: Placebo + Nivolumab + Bevacizumab", "arm_internal_id": 1, "arm_description": {}, "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Drug: Nivolumab", "level_internal_id": 0, "level_suspended": "N"}, {"level_code": "1", "level_description": "Drug: Bevacizumab", "level_internal_id": 1, "level_suspended": "N"}, {"level_code": "2", "level_description": "Other: Placebo", "level_internal_id": 2, "level_suspended": "N"}]}], "match": [{"and": [{"clinical": {"oncotree_primary_diagnosis": "", "disease_status": ["", ""]}}, {"genomic": {"hugo_symbol": "", "variant_category": ""}}]}]}]}}